Answers are grounded in this paper and cite their sources.
Identifies MDM4 amplification in liposarcoma, suggesting a potential new oncogenic driver.
Atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDLPS) is typically characterized by MDM2 and/or CDK4 amplification. However, a subset lacks these alterations, suggesting alternative oncogenic drivers. We report a patient with recurrent retroperitoneal WDLPS who developed multiple relapses over more than 25 years. Histology demonstrated a well-differentiated morphology with extensive myxoid change, without evidence of dedifferentiation. Molecular profiling using next-generation sequencing (NGS) identified MDM4 amplification, together with mutations in PIK3CA and TERT . This finding supports MDM4 as a potential alternative driver in liposarcomagenesis, possibly correlating with a more indolent clinical course. Recognition of this rare alteration is important for accurate diagnosis and may have future therapeutic implications.
No takes yet. Share an insight, caveat, or question.
Sanromán et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: